SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.
Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J Jr, Trinh L, Wrin T, Petroplolous CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B.
Peluso MJ, et al. Among authors: torres l.
medRxiv [Preprint]. 2021 Mar 5:2021.03.03.21251639. doi: 10.1101/2021.03.03.21251639.
medRxiv. 2021.
PMID: 33688675
Free PMC article.
Updated.
Preprint.